Aleksandra Wlodek

Aleksandra Wlodek

Auto-generated profile, based on publicly available information

Aleksandra Wlodek

Isomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
AWAleksandra Wlodek
Aleksandra Wlodek
SKSteve G. Kendrew
Steve G. Kendrew
NCNigel J. Coates
Nigel J. Coates
AHAdam Hold
Adam Hold
JPJoanna Pogwizd
Joanna Pogwizd
MGMatthew A. Gregory
Matthew A. Gregory
Erythromycin, avermectin and rapamycin are clinically useful polyketide natural products produced on modular polyketide synthase multienzymes by an assembly-line process in which each module of enzymes in turn specifies attachment of a particular chemical unit. Although polyketide synthase encoding genes have been successfully engineered to produce novel analogues, the process can be relatively slow, inefficient, and frequently low-yielding. We now describe a method for rapidly recombining polyketide synthase gene clusters to replace, add or remove modules that, with high frequency, generates diverse and highly productive assembly lines. The method is exemplified in the rapamycin biosynthetic gene cluster where, in a single experiment, multiple strains were isolated producing new members of a rapamycin-related family of polyketides. The process mimics, but significantly accelerates, a plausible mechanism of natural evolution for modular polyketide synthases. Detailed sequence analysis of the recombinant genes provides unique insight into the design principles for constructing useful synthetic assembly-line multienzymes.